Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA. This story matters for Finance & Markets readers tracking trade. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. Trade-News.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily trade signal